Clinical trials: Vincristine, completed
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
The overall objective of this protocol is to improve the cure rate of relapsed precursor B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
- Trial name
- NCT01700946
- Testing
- dexamethasone, vincristine sulfate, rituximab
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL.
- Trial name
- NCT01889069
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 39 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Hoffmann-La Roche
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia…
- Trial name
- NCT00408005
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 215 sites in United States, Australia and 3 more
- Volunteers
- 1,895 people
- Sponsor
- National Cancer Institute (NCI)
Extraocular Retinoblastoma
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
This phase III trial is studying the side effects and how well giving combination chemotherapy together with autologous stem cell transplant and/or radiation therapy works in treating young patients with extraocular…
- Trial name
- NCT00554788
- Testing
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin
- Where
- 73 sites in United States, Argentina and 4 more
- Volunteers
- 60 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085202
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Melanoma
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics).
- Trial name
- NCT00145041
- Testing
- Vincristine Sulfate Liposomes Injection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Acrotech Biopharma Inc.
Leukemia, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
RATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00133991
- Testing
- Filgrastim, Rituximab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
- Trial name
- NCT00075582
- Testing
- conventional surgery, dactinomycin, cyclophosphamide
- Where
- 163 sites in United States, Australia and 4 more
- Volunteers
- 390 people
- Sponsor
- Children's Oncology Group
Lymphoma
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00107380
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 86 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma, B-Cell, Follicular Lymphoma
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated…
- Trial name
- NCT00634179
- Testing
- Bortezomib, Rituximab, Doxorubicin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Leukemia, Myelocytic, Acute
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
- Trial name
- NCT00136084
- Testing
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
- Where
- 8 sites in United States
- Volunteers
- 238 people
- Sponsor
- St. Jude Children's Research Hospital
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma
- Trial name
- NCT01055314
- Testing
- Cixutumumab, Cyclophosphamide, Dactinomycin
- Where
- 139 sites in United States, Australia and 2 more
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Rituximab and ABVD for Hodgkin's Patients
Primary Objective: To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.
- Trial name
- NCT00504504
- Testing
- Rituximab, Adriamycin, Bleomycin
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
High-Risk Neuroblastoma Chemotherapy Without G-CSF
Patients will be asked to participate in this study because patients have been diagnosed with high-risk neuroblastoma, a common childhood cancer which has aggressive features. If left untreated, high-risk neuroblastoma is fatal.
- Trial name
- SPRING (NCT02786719)
- Testing
- Topotecan, Cyclophosphamide, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine
Leukemia, Lymphocytic, Acute
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
This goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded…
- Trial name
- NCT00905034
- Testing
- Methotrexate, Vincristine, PEG-l-asparaginase
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
- Trial name
- NCT00136435
- Testing
- prednisone, doxorubicin, vincristine
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred).
- Trial name
- NCT00440726
- Testing
- Bortezomib, Dexamethasone, PEG-asparaginase
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 31 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Lymphoma
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor.
- Trial name
- NCT00594815
- Testing
- Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center